Omacor Special Precautions

Omacor should be used with caution in patients with known sensitivity or allergy to fish.
During treatment with Omacor, there is a fall in thromboxane A2 production.
No significant effect has been observed on the other coagulation factors.
Some studies with omega-3-acids demonstrated a prolongation of bleeding time, but the bleeding time reported in these studies has not exceeded normal limits and did not produce clinically significant bleeding episodes.
Clinical studies have not been done to thoroughly examine the combined effect of Omacor and concomitant anticoagulants.
Patients receiving treatment with Omacor and an anticoagulant or other drug affecting coagulation (eg., acetylsalicylic acid, warfarin, coumarin) should be monitored periodically, see Interactions.
It is recommended that routine monitoring of the entire lipid profile is undertaken.
As a possible rise in LDL-C has been shown in some studies with intake of Omacor 4d/day, LDL-C should therefore be monitored on a regular basis, especially in patients with type IV and V dyslipidaemia.
Omacor is not recommended as monotherapy in Type IIb dyslipidaemia. Statins are to be used as first line treatment with Omacor indicated as add-on therapy when control of the triglyceride levels is required.
Effects on ability to drive and use machines: Effects on ability to drive and use machines have not been studied. Nevertheless, Omacor is expected to have no or negligible influence on the ability to drive and use machines.
Use in Children: In the absence of efficacy and safety data, the use of this medication in children is not recommended.
Use in the Elderly: Clinical data regarding the use of Omacor in elderly patients over 70 years of age are limited.